A Phase-1 Study to Assess the Pharmacokinetics, Safety and Tolerability of AVP-786 in Healthy Volunteers

A Phase 1, Single-center, Randomized, Open-label Study to Assess the Pharmacokinetics, Safety and Tolerability of AVP-786 (Deuterated [d6] Dextromethorphan Hydrobromide/Quinidine Sulfate) in Healthy Volunteers

To assess the multiple-dose pharmacokinetics (PK), safety and tolerability of AVP-786 (deuterated [d6] dextromethorphan hydrobromide [DM]/quinidine sulfate [Q]) in healthy volunteers.

Inclusion Criteria:

• Healthy adult males
• 18 - 45 years of age
• BMI 18 - 30 kg/m2

Exclusion Criteria:

• History or presence of significant disease
• History of substance abuse and/or alcohol abuse with the past 3 years
• Use of tobacco-containing or nicotine-containing products within 6 months
• Use of any prescription or the over-the-counter medications within 14 days